These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2975448)

  • 1. Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine.
    Scheiermann N; Gesemann KM; Paar D; Maurer C
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 269(3):411-21. PubMed ID: 2975448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a recombinant yeast-derived hepatitis B vaccine in healthy adults.
    Scheiermann N; Gesemann KM; Kreuzfelder E; Paar D
    Postgrad Med J; 1987; 63 Suppl 2():115-9. PubMed ID: 3317345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults.
    Just M; Berger R; Just V
    Postgrad Med J; 1987; 63 Suppl 2():121-3. PubMed ID: 3317346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology.
    Zahradnik JM; Couch RB; Gerin JL
    J Infect Dis; 1987 May; 155(5):903-8. PubMed ID: 2951449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Booster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccine.
    Chan CY; Lee SD; Tsai YT; Lo KJ
    Vaccine; 1991 Oct; 9(10):765-7. PubMed ID: 1836920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of low doses of recombinant hepatitis B vaccine in young males.
    Tsakalakis C; Richardson SC; Roumeliotou-Karayannis A; Papaevangelou G
    Vaccine; 1988 Aug; 6(4):328-30. PubMed ID: 2973188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose range study in healthy volunteers of a hepatitis B vaccine produced in yeast.
    Kuwert E; Scheiermann N; Gesemann M; Paar D; Safary A; Simoen E; Hauser P; Andre F
    Antiviral Res; 1985; Suppl 1():281-8. PubMed ID: 2935080
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients.
    Jilg W; Schmidt M; Weinel B; Küttler T; Brass H; Bommer J; Müller R; Schulte B; Schwarzbeck A; Deinhardt F
    J Hepatol; 1986; 3(2):190-5. PubMed ID: 3794300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules.
    Scheiermann N; Gesemann M; Maurer C; Just M; Berger R
    Vaccine; 1990 Mar; 8 Suppl():S44-6; discussion S60-2. PubMed ID: 2139282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
    Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
    Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers.
    Dahl-Hansen E; Siebke JC; Frøland SS; Degré M
    Epidemiol Infect; 1990 Feb; 104(1):143-9. PubMed ID: 2137785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactogenicity and immunogenicity of different lots of a yeast-derived hepatitis B vaccine.
    Wiedermann G; Ambrosch F; Kremsner P; Kunz C; Hauser P; Simoen E; André F; Safary A
    Postgrad Med J; 1987; 63 Suppl 2():109-13. PubMed ID: 3317344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults.
    Dentico P; Buongiorno R; Volpe A; Zavoianni A; Pastore G; Schiraldi O
    Eur J Epidemiol; 1992 Sep; 8(5):650-5. PubMed ID: 1426164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine.
    Just M; Berger R; Scheiermann N
    Vaccine; 1988 Oct; 6(5):401-2. PubMed ID: 2973694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
    Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines.
    Söyletir G; Bahçeci E; Akoğlu E; Soyoğul U; Lawrance RA
    Vaccine; 1992; 10(5):301-4. PubMed ID: 1533478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes.
    del Canho R; Grosheide PM; Voogd M; Huisman WM; Heijtink RA; Schalm SW
    J Med Virol; 1993 Sep; 41(1):30-4. PubMed ID: 8228934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.